Tags

Type your tag names separated by a space and hit enter

Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols.
Pediatr Dev Pathol. 2004 Jul-Aug; 7(4):342-7.PD

Abstract

Ewing sarcoma is a small round blue cell tumor with a high incidence of metastasis and poor survival. The tyrosine kinase receptor, c-kit, is a growth factor receptor that is expressed in a variety of tumors including Ewing sarcoma. Blockade of c-kit by imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ) has been successfully used in the treatment of chronic myelogenous leukemia and gastrointestinal tumors. Detection of c-kit expression in Ewing sarcoma indicates a possible role of c-kit in tumor progression and a potential use of anti-c-kit therapy in Ewing sarcoma. Ki-67 is a proliferation marker found at all stages of the cell cycle. Expression of c-kit and Ki-67 was studied in 17 patients with Ewing sarcoma. Sections from paraffin-embedded tumor samples were immunostained, using standard immunohistochemical protocols, with c-kit and Ki-67 monoclonal antibodies, polyclonal c-kit antibody without antigen retrieval, and c-kit polyclonal antibody with antigen retrieval. Eleven out of 17 cases (65%) stained with c-kit monoclonal antibody; the staining was diffuse in 6/17 (35%) cases. C-kit expression did not correlate with Ki-67 proliferation rates. Using the polyclonal c-kit-antibody without antigen retrieval methods, c-kit expression was demonstrated in 1/11 (9%) cases. Incorporating antigen retrieval methods, c-kit expression increased to 53%. Concordance between monoclonal antibodies in detecting c-kit expression was observed in 12/17 cases (71%). We conclude that c-kit is variably expressed in Ewing sarcoma, using either monoclonal or polyclonal antibodies. Detection of c-kit expression in Ewing sarcoma improves with the use of antigen retrieval methods.

Authors+Show Affiliations

Section of Pediatric Tumor Biology and Ultrastructural Pathology, National Cancer Institute, NIH Building 10, Rm 2A10, 10 Center Drive, 20892, Bethesda, MD, USA. ahmeda@mail.nih.govNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15383930

Citation

Ahmed, Atif, et al. "Expression of C-kit in Ewing Family of Tumors: a Comparison of Different Immunohistochemical Protocols." Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, vol. 7, no. 4, 2004, pp. 342-7.
Ahmed A, Gilbert-Barness E, Lacson A. Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols. Pediatr Dev Pathol. 2004;7(4):342-7.
Ahmed, A., Gilbert-Barness, E., & Lacson, A. (2004). Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols. Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 7(4), 342-7.
Ahmed A, Gilbert-Barness E, Lacson A. Expression of C-kit in Ewing Family of Tumors: a Comparison of Different Immunohistochemical Protocols. Pediatr Dev Pathol. 2004 Jul-Aug;7(4):342-7. PubMed PMID: 15383930.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols. AU - Ahmed,Atif, AU - Gilbert-Barness,Enid, AU - Lacson,Atilano, Y1 - 2004/06/17/ PY - 2002/08/02/received PY - 2004/02/11/accepted PY - 2004/9/24/pubmed PY - 2005/2/23/medline PY - 2004/9/24/entrez SP - 342 EP - 7 JF - Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society JO - Pediatr. Dev. Pathol. VL - 7 IS - 4 N2 - Ewing sarcoma is a small round blue cell tumor with a high incidence of metastasis and poor survival. The tyrosine kinase receptor, c-kit, is a growth factor receptor that is expressed in a variety of tumors including Ewing sarcoma. Blockade of c-kit by imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ) has been successfully used in the treatment of chronic myelogenous leukemia and gastrointestinal tumors. Detection of c-kit expression in Ewing sarcoma indicates a possible role of c-kit in tumor progression and a potential use of anti-c-kit therapy in Ewing sarcoma. Ki-67 is a proliferation marker found at all stages of the cell cycle. Expression of c-kit and Ki-67 was studied in 17 patients with Ewing sarcoma. Sections from paraffin-embedded tumor samples were immunostained, using standard immunohistochemical protocols, with c-kit and Ki-67 monoclonal antibodies, polyclonal c-kit antibody without antigen retrieval, and c-kit polyclonal antibody with antigen retrieval. Eleven out of 17 cases (65%) stained with c-kit monoclonal antibody; the staining was diffuse in 6/17 (35%) cases. C-kit expression did not correlate with Ki-67 proliferation rates. Using the polyclonal c-kit-antibody without antigen retrieval methods, c-kit expression was demonstrated in 1/11 (9%) cases. Incorporating antigen retrieval methods, c-kit expression increased to 53%. Concordance between monoclonal antibodies in detecting c-kit expression was observed in 12/17 cases (71%). We conclude that c-kit is variably expressed in Ewing sarcoma, using either monoclonal or polyclonal antibodies. Detection of c-kit expression in Ewing sarcoma improves with the use of antigen retrieval methods. SN - 1093-5266 UR - https://www.unboundmedicine.com/medline/citation/15383930/Expression_of_c_kit_in_Ewing_family_of_tumors:_a_comparison_of_different_immunohistochemical_protocols_ L2 - http://journals.sagepub.com/doi/full/10.1007/s10024-002-0077-y?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -